Understanding RILD's clinical characteristics is essential for effective management in patients undergoing immunochemotherapy ...

A preliminary study showed that four weekly doses of intravenous rituximab, an anti-B-cell antibody, reduced proteinuria in patients with idiopathic membranous nephropathy, but individual ...

To stabilize this condition we started rituximab therapy immediately after the third cycle of immunoadsorption, with 375 mg/m 2 rituximab being administered intravenously once weekly for 4 weeks.

APG-2575（Lisaftoclax）是亚盛医药自主研发的、具全球best-in-class潜力的新型口服Bcl-2选择性抑制剂，在多种血液肿瘤和实体瘤治疗领域具备广阔的治疗潜力。亚盛医药将在此次ASH年会上，口头报告该品种治疗复发/难治（R/R）多发性骨髓瘤 ...

Tacrolimus, cyclosporin, mycophenolate mofetil, and levamisole may reduce the risk of relapse in children with frequently relapsing nephrotic syndrome. Cyclophosphamide and chlorambucil compared with ...

Celltrion’s biosimilar marketing strategy in Europe has got seriously confusing after the firm asked to market its rituximab near-copy under four different brands. Its biosimilar of Roche’s ...

Stephens initiates coverage on ADC Therapeutics (ADCT), highlighting Zynlonta's potential in second-line DLBCL and a ...

Late-onset neutropenia (LON) is emerging as a common adverse effect to rituximab therapy owing to widespread use of this drug in the treatment of B-cell lymphomas and autoimmune diseases.

Groundbreaking bone marrow transplant saves 10-month-old boy with rare genetic immunodeficiency, funded by The Hans ...

Moreover, high-efficacy monoclonal antibody therapy -- ocrelizumab (Ocrevus), rituximab (Rituxan), or natalizumab (Tysabri) - ...

Prolonged Follow-up Confirms Positive Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) on Outcomes #469 oral presentation Session: 626.

The therapy works by genetically modifying cells to enable the body’s own immune system to recognise and attack problem cells ...